2,385 results on '"Grant, Steven"'
Search Results
152. Data from PERK–Dependent Regulation of Ceramide Synthase 6 and Thioredoxin Play a Key Role in mda-7/IL-24–Induced Killing of Primary Human Glioblastoma Multiforme Cells
153. Supplementary Figure 1 from CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies
154. Supplementary Figure 8 from MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma
155. Data from Mechanism by Which Mcl-1 Regulates Cancer-Specific Apoptosis Triggered by mda-7/IL-24, an IL-10–Related Cytokine
156. Supplementary Figures 1-8 from Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway
157. Supplementary Figure 2 from CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies
158. Supplementary Figure 4 from MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma
159. Supplementary Figure Legend from Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism
160. Supplementary Figure 6 from MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma
161. Supplementary Figures 1-11 from PERK–Dependent Regulation of Ceramide Synthase 6 and Thioredoxin Play a Key Role in mda-7/IL-24–Induced Killing of Primary Human Glioblastoma Multiforme Cells
162. Supplementary Figures 1-6 from The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation
163. Supplementary Figure 7 from MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma
164. Supplementary Video 3 from CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies
165. Supplementary Table 1 from Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism
166. Supplementary Figure Legend from MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma
167. Supplementary Methods, Figures 1-4 from Mechanism of Autophagy to Apoptosis Switch Triggered in Prostate Cancer Cells by Antitumor Cytokine Melanoma Differentiation-Associated Gene 7/Interleukin-24
168. Supplementary Figure 2 from MDA-9/Syntenin and IGFBP-2 Promote Angiogenesis in Human Melanoma
169. Augmenting Venetoclax Activity Through Signal Transduction in AML
170. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
171. Activation of Memory Circuits during Cue-Elicited Cocaine Craving
172. Selective body biasing for post-silicon tuning of sub-threshold designs: A semi-infinite programming approach with Incremental Hypercubic Sampling
173. Update on rational targeted therapy in AML
174. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR
175. Construction & expression in E. coli of novel single-chain antibody fragments against the herbicide atrazine
176. Reactivity-Guided Isolation and Medicinal Chemistry of Marine Bacterial Natural Products
177. Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition
178. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
179. A new color-changing species of Corydoras (Siluriformes: Callichthyidae) from the rio Jutaí, Brazilian Amazon.
180. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells.
181. Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
182. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
183. Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
184. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax
185. A new color-changing species of Corydoras (Siluriformes: Callichthyidae) from the rio Jutaí, Brazilian Amazon
186. Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
187. Investigating Analyte Breakthrough Under Non-Linear Isotherm Conditions During Solid Phase Extraction Facilitated by Non-Targeted Analysis with Comprehensive Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry
188. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation
189. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells
190. Current advances in ER stress intervention therapies
191. Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance
192. Disrupting autophagy in FLT3-mutant acute myeloid leukemia
193. Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
194. Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma
195. Non-canonical Role for the Ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells
196. Functional role of DNMT1 in the anti-leukemic effects of hypomethylating agents in AML cells
197. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis
198. Phase field fracture model for additively manufactured metallic materials
199. The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy
200. CDK Inhibitors in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.